Drugs / AZD4916
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06951880 | Jul 2026 → Oct 2027 expected | — | AstraZeneca | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06951880 ↗ |
| Route | Oral | “AZD4916 will be administered as oral solution.” NCT06951880 ↗ |